ugt-58 Antibody
Description
UGT Antibody Nomenclature and Families
The UDP-glucuronosyltransferase (UGT) superfamily is divided into four main families in humans: UGT1, UGT2, UGT3, and UGT8 . These enzymes are further categorized into subfamilies (e.g., UGT1A, UGT2B) based on sequence homology and substrate specificity. Antibodies targeting UGTs are typically labeled according to their specific isoform (e.g., UGT1A1, UGT2B7) .
Key Points:
-
No UGT-58 isoform has been identified in genomic or proteomic studies of the UGT superfamily .
-
Existing antibodies target well-characterized isoforms, such as UGT1A (e.g., 1A1, 1A6) and UGT2B (e.g., 2B7, 2B17) .
Documented UGT Antibodies
Commercial and research-grade antibodies against UGTs are strictly mapped to validated isoforms. For example:
| Antibody | Target Isoform | Reactivity | Applications | Source |
|---|---|---|---|---|
| UGT Antibody #4371 | Pan-UGT1A | Human, Mouse, Rat | Western Blotting | Cell Signaling Tech |
| Anti-UGT2B17 | UGT2B17 | Human | IHC, ELISA | Custom-developed |
These antibodies are critical for studying UGT expression in cancer, drug metabolism, and glucuronidation pathways .
Potential Causes of Nomenclature Confusion
The term "ugt-58" may stem from:
-
Typographical errors (e.g., "UGT1A8" or "UGT2B15" mislabeled as "58").
-
Nonstandard labeling in proprietary datasets not yet peer-reviewed.
-
Species-specific isoforms (e.g., rodent UGTs), though these follow distinct numbering conventions (e.g., rat Ugt1a7) .
Research Recommendations
To resolve ambiguities:
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
FAQs for Researchers on UGT-58 Antibody in Academic Research
Advanced Research Questions
-
How to resolve discrepancies in UGT-58 expression levels across cancer studies?
-
Methodological Answer:
-
Tissue Heterogeneity: Normalize expression data to tumor purity scores (e.g., via ESTIMATE algorithm) .
-
Batch Effect Correction: Apply ComBat or similar tools to harmonize data from different platforms .
-
Functional Validation: Pair mRNA expression with enzymatic activity assays (e.g., UDP-glycosyltransferase activity in microsomal fractions) .
-
Meta-Analysis: Compare results across cohorts (e.g., TCGA vs. CPTAC) to identify consensus patterns .
-
-
-
What role does UGT-58 play in drug resistance mechanisms?
-
Methodological Answer:
-
Ceramide Glycosylation Assays: Measure glycosphingolipid levels in UGT-58-overexpressing cancer cells using LC-MS .
-
Drug Sensitivity Profiling: Treat UGT-58 KO cells with adriamycin or ceramide analogs and assess apoptosis via flow cytometry .
-
Transcriptomic Analysis: Link UGT-58 expression to ABC transporter genes (e.g., ABCB1) using co-expression networks .
-
-
Data Contradiction Analysis
-
Why do some studies associate high UGT-58 with good prognosis in colon cancer but poor prognosis in adrenocortical carcinoma?
Technical Optimization
-
How to troubleshoot nonspecific bands in UGT-58 Western blots?
-
Methodological Answer:
-
Pre-absorption: Incubate antibody with liver microsomes (rich in nonspecific UGTs) to remove cross-reactive antibodies .
-
Gel Electrophoresis: Use 10% SDS-PAGE to resolve the 61 kDa UGT-58 band from nearby isoforms (e.g., UGT1A at 50–55 kDa) .
-
Validation: Confirm band identity using CRISPR-Cas9 knockout cell lines .
-
-
Therapeutic Implications
-
Can UGT-58 somatic mutations serve as biomarkers for drug response?
-
Methodological Answer:
-
Mutation Screening: Use targeted sequencing panels (e.g., Ion AmpliSeq) to detect UGT-58 mutations in tumor DNA .
-
Functional Impact: Classify mutations using in silico tools (e.g., SIFT, PolyPhen-2) and validate catalytic activity in vitro .
-
Clinical Correlation: Link mutation status to patient survival in public datasets (e.g., cBioPortal) .
-
-
